---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-066931"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:05:04.929462+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Catalyst launches AGAMREE (vamorolone) in US for Duchenne Muscular Dystrophy

## Summary
- AGAMREE (vamorolone) oral suspension 40 mg/mL now commercially available by prescription for DMD patients aged 2+.
- FDA approved Oct 26, 2023; launch follows approval with nationwide specialty pharmacy network.
- Pivotal Phase 2b VISION-DMD study showed comparable efficacy with reduced bone health and growth side effects vs. standard corticosteroids.
- Catalyst Pathways patient support program provides one-on-one education and financial assistance for eligible patients.
- DMD affects ~11,000–13,000 US patients; ~70% currently on corticosteroid therapy.

## SEC filing metadata
- accession: 0001193125-24-066931
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524066931/0001193125-24-066931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524066931/d798971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-066931
- JSON: https://secwatch.observer/filing/0001193125-24-066931.json
- Plain text: https://secwatch.observer/filing/0001193125-24-066931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.